To stimulate strong anti-tumor immune responses, cancer immunotherapy typically employs immune checkpoint inhibitors for the PD-1/PD-L1 and CTLA-4 pathways to amplify immune system responses and also to harnesses responses to neoantigens that are primarily tumor-specific antigens resulting from the higher mutation load in tumor cells (27–29). The gene discussed is PDCD1; the disease is neoplasm.